vs

Side-by-side financial comparison of ALPHA & OMEGA SEMICONDUCTOR Ltd (AOSL) and Orthofix Medical Inc. (OFIX). Click either name above to swap in a different company.

Orthofix Medical Inc. is the larger business by last-quarter revenue ($219.9M vs $162.3M, roughly 1.4× ALPHA & OMEGA SEMICONDUCTOR Ltd). Orthofix Medical Inc. runs the higher net margin — -1.0% vs -8.2%, a 7.2% gap on every dollar of revenue. On growth, Orthofix Medical Inc. posted the faster year-over-year revenue change (2.0% vs -6.3%). Orthofix Medical Inc. produced more free cash flow last quarter ($16.8M vs $-23.1M). Over the past eight quarters, Orthofix Medical Inc.'s revenue compounded faster (8.0% CAGR vs 4.0%).

Alpha & Omega Semiconductor Ltd designs, manufactures and markets a broad portfolio of power semiconductors, including power MOSFETs, IGBTs, analog ICs and power management modules. Its products are applied across consumer electronics, industrial equipment, automotive systems, telecom and computing segments, with sales networks covering major global markets.

Orthofix Medical Inc. is a global medical device firm specializing in orthopedic care. It develops, manufactures and sells spinal implants, trauma care products, bone growth stimulation therapies and regenerative medicine offerings, serving orthopedic surgeons and healthcare providers across North America, Europe and Asia Pacific.

AOSL vs OFIX — Head-to-Head

Bigger by revenue
OFIX
OFIX
1.4× larger
OFIX
$219.9M
$162.3M
AOSL
Growing faster (revenue YoY)
OFIX
OFIX
+8.3% gap
OFIX
2.0%
-6.3%
AOSL
Higher net margin
OFIX
OFIX
7.2% more per $
OFIX
-1.0%
-8.2%
AOSL
More free cash flow
OFIX
OFIX
$39.9M more FCF
OFIX
$16.8M
$-23.1M
AOSL
Faster 2-yr revenue CAGR
OFIX
OFIX
Annualised
OFIX
8.0%
4.0%
AOSL

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
AOSL
AOSL
OFIX
OFIX
Revenue
$162.3M
$219.9M
Net Profit
$-13.3M
$-2.2M
Gross Margin
21.5%
71.1%
Operating Margin
-8.4%
0.2%
Net Margin
-8.2%
-1.0%
Revenue YoY
-6.3%
2.0%
Net Profit YoY
-101.0%
92.4%
EPS (diluted)
$-0.45
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AOSL
AOSL
OFIX
OFIX
Q4 25
$162.3M
$219.9M
Q3 25
$182.5M
$205.6M
Q2 25
$176.5M
$203.1M
Q1 25
$164.6M
$193.6M
Q4 24
$173.2M
$215.7M
Q3 24
$181.9M
$196.6M
Q2 24
$161.3M
$198.6M
Q1 24
$150.1M
$188.6M
Net Profit
AOSL
AOSL
OFIX
OFIX
Q4 25
$-13.3M
$-2.2M
Q3 25
$-2.1M
$-22.8M
Q2 25
$-77.1M
$-14.1M
Q1 25
$-10.8M
$-53.1M
Q4 24
$-6.6M
$-29.1M
Q3 24
$-2.5M
$-27.4M
Q2 24
$-2.7M
$-33.4M
Q1 24
$-11.2M
$-36.0M
Gross Margin
AOSL
AOSL
OFIX
OFIX
Q4 25
21.5%
71.1%
Q3 25
23.5%
72.2%
Q2 25
23.4%
68.7%
Q1 25
21.4%
62.8%
Q4 24
23.1%
69.0%
Q3 24
24.5%
68.7%
Q2 24
25.7%
67.8%
Q1 24
23.7%
67.5%
Operating Margin
AOSL
AOSL
OFIX
OFIX
Q4 25
-8.4%
0.2%
Q3 25
-2.5%
-8.3%
Q2 25
-6.6%
-7.9%
Q1 25
-6.5%
-25.2%
Q4 24
-3.4%
-5.3%
Q3 24
-0.1%
-9.6%
Q2 24
-0.9%
-12.5%
Q1 24
-7.0%
-15.6%
Net Margin
AOSL
AOSL
OFIX
OFIX
Q4 25
-8.2%
-1.0%
Q3 25
-1.2%
-11.1%
Q2 25
-43.7%
-6.9%
Q1 25
-6.6%
-27.4%
Q4 24
-3.8%
-13.5%
Q3 24
-1.4%
-13.9%
Q2 24
-1.7%
-16.8%
Q1 24
-7.5%
-19.1%
EPS (diluted)
AOSL
AOSL
OFIX
OFIX
Q4 25
$-0.45
$-0.05
Q3 25
$-0.07
$-0.57
Q2 25
$-2.61
$-0.36
Q1 25
$-0.37
$-1.35
Q4 24
$-0.23
$-0.76
Q3 24
$-0.09
$-0.71
Q2 24
$-0.09
$-0.88
Q1 24
$-0.39
$-0.95

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AOSL
AOSL
OFIX
OFIX
Cash + ST InvestmentsLiquidity on hand
$196.3M
$82.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$818.8M
$450.0M
Total Assets
$1.0B
$850.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AOSL
AOSL
OFIX
OFIX
Q4 25
$196.3M
$82.0M
Q3 25
$223.5M
$62.9M
Q2 25
$153.1M
$65.6M
Q1 25
$169.4M
$58.0M
Q4 24
$182.6M
$83.2M
Q3 24
$176.0M
$30.1M
Q2 24
$175.1M
$26.4M
Q1 24
$174.4M
$27.0M
Total Debt
AOSL
AOSL
OFIX
OFIX
Q4 25
Q3 25
$157.2M
Q2 25
$14.9M
$157.0M
Q1 25
$156.9M
Q4 24
$157.0M
Q3 24
$118.5M
Q2 24
$26.7M
$118.0M
Q1 24
$118.2M
Stockholders' Equity
AOSL
AOSL
OFIX
OFIX
Q4 25
$818.8M
$450.0M
Q3 25
$834.1M
$442.5M
Q2 25
$822.3M
$458.3M
Q1 25
$886.3M
$458.3M
Q4 24
$902.6M
$503.1M
Q3 24
$895.3M
$525.9M
Q2 24
$891.6M
$546.0M
Q1 24
$888.9M
$570.3M
Total Assets
AOSL
AOSL
OFIX
OFIX
Q4 25
$1.0B
$850.6M
Q3 25
$1.0B
$832.6M
Q2 25
$1.0B
$837.2M
Q1 25
$1.1B
$823.1M
Q4 24
$1.1B
$893.3M
Q3 24
$1.1B
$867.9M
Q2 24
$1.1B
$882.0M
Q1 24
$1.2B
$906.0M
Debt / Equity
AOSL
AOSL
OFIX
OFIX
Q4 25
Q3 25
0.36×
Q2 25
0.02×
0.34×
Q1 25
0.34×
Q4 24
0.31×
Q3 24
0.23×
Q2 24
0.03×
0.22×
Q1 24
0.21×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AOSL
AOSL
OFIX
OFIX
Operating Cash FlowLast quarter
$-8.1M
$27.7M
Free Cash FlowOCF − Capex
$-23.1M
$16.8M
FCF MarginFCF / Revenue
-14.2%
7.6%
Capex IntensityCapex / Revenue
9.2%
4.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-40.9M
$-1.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AOSL
AOSL
OFIX
OFIX
Q4 25
$-8.1M
$27.7M
Q3 25
$10.2M
$12.4M
Q2 25
$-2.8M
$11.6M
Q1 25
$7.4M
$-18.4M
Q4 24
$14.1M
$23.7M
Q3 24
$11.0M
$11.7M
Q2 24
$7.1M
$9.0M
Q1 24
$28.2M
$-18.6M
Free Cash Flow
AOSL
AOSL
OFIX
OFIX
Q4 25
$-23.1M
$16.8M
Q3 25
$420.0K
$2.5M
Q2 25
$-17.2M
$4.5M
Q1 25
$-1.1M
$-25.1M
Q4 24
$6.6M
$15.2M
Q3 24
$4.1M
$6.3M
Q2 24
$-210.0K
$-360.0K
Q1 24
$20.5M
$-29.1M
FCF Margin
AOSL
AOSL
OFIX
OFIX
Q4 25
-14.2%
7.6%
Q3 25
0.2%
1.2%
Q2 25
-9.7%
2.2%
Q1 25
-0.6%
-13.0%
Q4 24
3.8%
7.0%
Q3 24
2.3%
3.2%
Q2 24
-0.1%
-0.2%
Q1 24
13.7%
-15.4%
Capex Intensity
AOSL
AOSL
OFIX
OFIX
Q4 25
9.2%
4.9%
Q3 25
5.4%
4.8%
Q2 25
8.1%
3.5%
Q1 25
5.1%
3.5%
Q4 24
4.3%
4.0%
Q3 24
3.8%
2.7%
Q2 24
4.5%
4.7%
Q1 24
5.2%
5.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AOSL
AOSL

Power Discrete$101.0M62%
Power Ic$58.8M36%
Packaging And Testing Services$2.5M2%

OFIX
OFIX

Spinal Implants Biologics And Enabling Technologies$113.6M52%
Bone Growth Therapies$68.3M31%
Other$22.7M10%
IT$5.9M3%
GB$3.5M2%
FR$3.5M2%
DE$2.3M1%

Related Comparisons